JUNE 30, 2021
Biophytis Secures the Manufacturing of Sarconeos (BIO101) for COVID-19 with a Global CDMO & Announces the Next Milestones for the COVA Phase 2-3 Study Fullscreen Mode
JUNE 30, 2021
Results of Biophytis SARA-INT Phase 2 Trial with Sarconeos (BIO101) in Sarcopenia will be Released by August 2021.
JUNE 18, 2021
Biophytis announces new convertible bonds financing up to €32 million with Atlas and drawing of 2 tranches under the 2020 Atlas Contract for €6 million
MAY 12, 2021
Biophytis Completed Recruitment of 155 Participants to the COVA Phase 2-3 Study with Sarconeos (BIO101) in COVID-19 allowing the 2nd Interim Analysis.
MAY 11, 2021
Results of the Combined General Meeting on May 10, 2021
APRIL 30, 2021
Biophytis – Second Combined General Meeting to Take Place on May 10, 2021 without the physical presence of its shareholders
APRIL 29, 2021
Biophytis receives €980,000 DeepTech Funding from BPI France for the Development of Macuneos (BIO201) in Dry AMD
APRIL 27, 2021
Biophytis – Convening of Another Combined General Meeting at a Later Date
APRIL 26, 2021
Biophytis gives operational perspectives on its Sarconeos (BIO101) ahead of its upcoming AGM on April 26, 2021
APRIL 13, 2021
Biophytis Identifies False Report Regarding COVA Study